This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Changzhou Le Sun Pharmaceuticals Limited, Changzhou Qianhong Biopharma Co., Ltd.. Active years: 2023.
Company Filing History:
1 out of 3 
1 out of 1 Years Active: 2023
Title: Jinchen Lv: Innovator in Protein Kinase Inhibition
Introduction
Jinchen Lv is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of selective inhibitors for protein kinases. His work is crucial in the fight against proliferative disorders, including cancer.
Latest Patents
Jinchen Lv holds a patent for a tartrate of a selective CDK9 inhibitor and its crystal form. This invention, which includes a tartrate of 3-(5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)-benzenesulfonamide, is designed to inhibit cyclin-dependent kinase 9 (CDK9). The application of this patent is particularly relevant in treating various diseases associated with protein kinase/CDK activity.
Career Highlights
Throughout his career, Jinchen Lv has worked with prominent companies in the biopharmaceutical sector. He has been associated with Changzhou Qianhong Biopharma Co., Ltd. and Changzhou Le Sun Pharmaceuticals Limited. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Jinchen Lv has collaborated with notable colleagues, including Shudong Wang and Hui Wang. These partnerships have likely enhanced his research and development efforts in the field of protein kinase inhibitors.
Conclusion
Jinchen Lv's contributions to the field of biopharmaceuticals, particularly through his patent on selective CDK9 inhibitors, highlight his role as an innovator. His work continues to pave the way for advancements in the treatment of cancer and other related diseases.